PRAS40 suppresses atherogenesis through inhibition of mTORC1-dependent pro-inflammatory signaling in endothelial cells

Abstract

Endothelial pro-inflammatory activation plays a pivotal role in atherosclerosis, and many pro-inflammatory and atherogenic signals converge upon mechanistic target of rapamycin (mTOR). Inhibitors of mTOR complex 1 (mTORC1) reduced atherosclerosis in preclinical studies, but side effects including insulin resistance and dyslipidemia limit their clinical use in this context. Therefore, we investigated PRAS40, a cell type-specific endogenous modulator of mTORC1, as alternative target. Indeed, we previously found PRAS40 gene therapy to improve metabolic profile; however, its function in endothelial cells and its role in atherosclerosis remain unknown. Here we show that PRAS40 negatively regulates endothelial mTORC1 and pro-inflammatory signaling. Knockdown of PRAS40 in endothelial cells promoted TNFα-induced mTORC1 signaling, proliferation, upregulation of inflammatory markers and monocyte recruitment. In contrast, PRAS40-overexpression blocked mTORC1 and all measures of pro-inflammatory signaling. These effects were mimicked by pharmacological mTORC1-inhibition with torin1. In an in vivo model of atherogenic remodeling, mice with induced endothelium-specific PRAS40 deficiency showed enhanced endothelial pro-inflammatory activation as well as increased neointimal hyperplasia and atherosclerotic lesion formation. These data indicate that PRAS40 suppresses atherosclerosis via inhibition of endothelial mTORC1-mediated pro-inflammatory signaling. In conjunction with its favourable effects on metabolic homeostasis, this renders PRAS40 a potential target for the treatment of atherosclerosis.

Transcriptomic Changes Associated with Loss of Cell Viability Induced by Oxysterol Treatment of a Retinal Photoreceptor-Derived Cell Line: An In Vitro Model of Smith–Lemli–Opitz Syndrome

“…It is intriguing in this respect that 7kCHOL up-regulated Rictor and Protor2 , both specific for mTorc2, generally considered to be an activating factor for Akt, and therefore whose potentiation would be assumed to attenuate cell death processes [ 78 ]. Engagement and interactions of additional mTORC pathway DEGs depicted in Figure 13 have been described [ 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 ].…”

A Boolean approach for novel hypoxia-related gene discovery

“…In the context to our current finding, AKT1S1 is known to be activated by hypoxia [ 41 ]. Its activation in the nerve cells protect neuronal cell from damage [ 41 ] and in endothelial cells, it suppresses atherogenesis [ 42 ], both through inhibition of mTORC1 signaling. Interestingly, both AKT1S1 and N4BP1 are known to oppositely regulate NF-κB transcriptional activity.…”

mTOR (Mammalian Target of Rapamycin): Hitting the Bull’s Eye for Enhancing Neurogenesis After Cerebral Ischemia?

“…49,50 PRAS40 predominantly interacts with Raptor and negatively modulates mTORC1 activity by competitively suppressing the binding of mTORC1 substrates to Raptor, and upon activation, mTOR could straightly phosphorylate PRAS40, leading to the separation of PRAS40 from mTORC1. 51,52 DEPTOR, a mTOR-interacting protein, negatively mediates mTORC1 activity by binding to FAT domain, 53 and mLST8 interacts with the kinase domain of mTOR and promotes the stabilization and activity of mTORC1. 54…”